Pfizer Inc.: enforcement record and regulatory exposure
Pfizer Inc. scores 84 out of 100 on the RedFlag Index™ (October 2026), ranking #1 of ten tracked companies, with 7 documented cases of which 4 remain open.
Documented record
Pfizer has paid about $11.3 billion in tracked penalties since 2000.
2025: Pfizer and Tris Pharma agreed to pay Texas $41.5 million over allegations they supplied adulterated ADHD drug Quillivant to Medicaid.
2024: Independent drug-pricing watchdog ICER rated Vyndamax "low" value and said a fair price would be $13,600–$39,000 a year, an 85–95% cut.
2016: Pfizer subsidiary Wyeth paid $784.6 million to resolve False Claims Act allegations of underpaying Medicaid rebates on Protonix.
2009: Pfizer paid $2.3 billion for off-label promotion and kickbacks on Bextra, Geodon, Zyvox, and Lyrica. This included a $1.195 billion criminal fine, then the largest in U.S. history.
2004: Warner-Lambert, acquired by Pfizer in 2000, paid $430 million over off-label promotion of Neurontin.
RegulationWatch coverage
- Drug Promotion
Pfizer markets Vyndamax as the "only once-daily capsule". The evidence says otherwise.
Patients are not informed that a cheaper rival pill exists, or that Pfizer paid the support group it recommends.
- State Enforcement
Florida sues Pfizer and Albert Bourla over vaccine marketing
Florida filed a consumer-protection lawsuit against Pfizer and its chief executive. Pfizer disputed the allegations.
- PBM Rebates
Vyndamax made $6 billion in 2025 with a cheaper rival on the market. The rebate system is built to protect incumbents like Pfizer.
Pharmacy benefit managers are paid more when list prices and rebates are higher. Two FTC settlements and a federal reform law have not yet changed that, and Pfizer's contracts stay secret.
- Anti-Kickback Statute
Pfizer paid $2.3 billion over kickbacks, then asked to pay Vyndamax patients' copays. Speaker fees are the route the law still leaves open.
The Anti-Kickback Statute bars paying doctors to prescribe. It still permits paying them to talk about the same drug, and patients never see who was paid.
- False Claims Act
Abbott agrees to nearly $385 million infant formula settlement
The Justice Department announced a settlement with Abbott Laboratories over allegedly noncompliant infant formula and nutritional products purchased through government programs. Abbott denied the allegations and did not admit facts or liability.
- Patent Litigation
Pfizer settled with three generic challengers and pushed Vyndamax competition to 2031. No court ruled its patents valid.
The settlements are private, their terms are undisclosed, and patients keep paying the branded price for up to two more years.
- False Claims Act
Pfizer pays $59.7 million over Biohaven kickbacks tied to migraine drug Nurtec
Pfizer agreed to pay $59,746,277 to resolve DOJ allegations that its subsidiary Biohaven, before the acquisition, paid kickbacks to health care providers to induce prescriptions of Nurtec ODT. The government alleged speaker honoraria and high-end meals violated the Anti-Kickback Statute between March 2020 and September 2022.
